CHICAGO and FORT WORTH, Texas, Dec. 15, 2025 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (ACTU) (“Actuate” or the “Company”), a clinical-stage biopharmaceutical company focused on developing ...
Clinical Study Evaluating a Long-Acting Naltrexone Implant Under the FDA's 505(b)(2) Pathway ANAHEIM, CA - January 14, 2026 (NEWMEDIAWIRE) - BioCorRx Inc. (OTCID: BICX) (the "Company"), a developer ...
*Important notice: arXiv publishes preliminary scientific reports that are not peer-reviewed and, therefore, should not be regarded as conclusive, guide clinical practice/health-related behavior, or ...
To support the design and conduct of clinical research in AKI Core A provides innovative clinical resources to support clinical and translational research in AKI. Firstly, the core provides consulting ...
Efficacy and Safety of Glofitamab Plus Polatuzumab Vedotin in Relapsed/Refractory Large B-Cell Lymphoma Including High-Grade B-Cell Lymphoma: Results From a Phase Ib/II Trial In this phase III trial, ...
Dynamic Treatment Regimes (DTRs) represent a paradigm shift in clinical care, moving from a one‐size‐fits‐all model to strategies that adapt treatment over time based on individual patient ...
Detailed price information for Casi Pharmaceuticals Inc (CASI-Q) from The Globe and Mail including charting and trades.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback